As BioJapan approaches, many overseas participants are asking themselves: Are we prepared not only with presentations and brochures, but also with the right approach to building trust with Japanese partners? This is a crucial question, because success at BioJapan is not only about showcasing technologies—it’s about understanding how Japanese pharma companies respond to CDMO sales approaches.
Recently, I had a chance to experience something unusual for me—I decided to sit through a life insurance sales pitch. It happened almost by coincidence: at a small local festival, an insurance company had set up a booth with activities where kids could play, and from there I was invited into their sales funnel. Normally, I find insurance discussions cumbersome, but I was curious to see how their sales method worked.
What struck me was the sheer length of the process. Even though this was a B2C case, it still took five separate meetings before we even began talking about the insurance. That experience reminded me of CDMO sales in Japan—if it takes five conversations just to talk about terms in consumer insurance, how much more deliberate and extended must the cycle be when it comes to high-stakes CDMO partnerships?
This also resonated with a conversation I had recently with a German colleague in the same industry, who has lived in Japan for years. He noted that earning trust from Japanese pharma companies takes far longer than in Europe, and that this slow-building trust dynamic is something foreign CDMOs often underestimate.
With these personal impressions in mind, I wanted to go beyond anecdote. In this article, I’ll combine those lived experiences with insights from academic studies and third-party business reports to explore how sales approaches differ between Japan, Europe, and the United States. In particular, I’ll focus on why persistent, “pushy” Western-style CDMO sales tactics often fail in Japan, and what approaches tend to resonate better with Japanese decision-makers—especially relevant for those preparing for BioJapan.
Trust and Decision-Making
Japanese pharma business culture places a premium on trust (shinyo) and long-term relationships. According to a report from the EU–Japan Centre, Japanese buyers are instinctively looking for reliable partners, but the process of proving that reliability must not be rushed. In practice, Japanese companies often require multiple rounds of meetings and careful consensus-building before moving forward. One study (EU–Japan Centre for Industrial Cooperation, 2021) suggested that multiple meetings are typical before meaningful terms are even discussed.
By contrast, in Europe and the U.S., ROI and speed often take precedence. Decision-making authority rests more with individuals, and contracts can be signed after a relatively short series of interactions. This makes Western CDMO sales processes faster, but also more transactional.
- Japan: group consensus, long-term trust, stability and quality as priorities.
- Europe/US: speed, ROI, innovation, and shorter sales cycles.
Communication Styles
Another key difference lies in communication. Japanese pharma culture favors indirect, polite, and measured exchanges, where relationship-building comes before problem-solving. CDMO sales often start at trade fairs like BioJapan, through introductions, or via referrals. Cold calls and aggressive email campaigns are not just ineffective—they are often seen as disrespectful.
In the U.S. and Europe, however, direct and assertive communication is often valued. Outreach strategies may include cold calls, mass email campaigns, and digital lead generation, with CRM tools driving systematic follow-ups. These methods aim for efficiency, but they can feel overly intrusive in Japan.
- Japan: in-person meetings, referrals, careful documentation, etiquette.
- Europe/US: digital campaigns, outbound calls, rapid proposal cycles.
The Problem with “Persistent” Sales
In the Japanese context, pushy CDMO sales are often counterproductive. Academic commentary highlights that aggressive calls-to-action (like “BUY NOW!”) rarely work. Once a Japanese pharma client feels pressured, they may retreat entirely. Cold calling, in particular, is considered both culturally inappropriate and legally constrained in many industries.
At the same time, persistence is not always seen negatively. When framed as sincere, respectful follow-up, multiple visits and careful check-ins can actually demonstrate commitment and seriousness. The key difference is tone: persistence without pushiness.
- Counterproductive: aggressive follow-ups, unsolicited calls, pressure tactics.
- Effective: repeated but respectful visits, steady presence at industry events, patience in building rapport.
Key Takeaways for CDMOs Having Meetings with Japanese Partners at BioJapan
- Patience is strategy: expect longer cycles—what takes one or two meetings in Europe may take five or more in Japan.
- Trust before transaction: Japanese pharma buyers need to feel confident in your reliability before they’ll move to terms.
- Adapt communication: avoid hard-sell emails and instead invest in introductions, trade shows like BioJapan, and face-to-face engagement.
- Persistence ≠ pushiness: follow-up is essential, but it must be respectful and relationship-oriented.
Conclusion
For European CDMOs & Biotechs, succeeding in Japan means slowing down to speed up. The Japanese pharma market rewards those who understand that building trust and credibility is not an obstacle but the very foundation of sustainable partnerships. Aggressive, transactional tactics may close deals quickly elsewhere, but in Japan, they risk closing doors permanently.
If this resonates with you and you’d like to discuss your Japan entry strategy, let’s schedule a conversation.